AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05253495
Drug: Bv-NVD-R, Cycle 1-4 RER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brentuximab vedotin x 2; nivolumab x 2; vinblastine x 2; dacarbazine x 2; rituximab x 2;
Trial: NCT05253495
Drug: Bv-NAVD-R, Cycle 1-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brentuximab vedotin x 2; nivolumab x 2; doxorubicin x 2; vinblastine x 2; dacarbazine x 2; rituximab x 2;
Trial: NCT04520490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly placebo injections
Trial: NCT05638282
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04753034
Drug: TER-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Comparator
Trial: NCT04753034
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT06493838
Drug: intravenous 50 mL of saline injection of 0.9% after umbilical cord clamping.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous 50 mL of saline injection of 0.9% after umbilical cord clamping.
Trial: NCT06306339
Drug: SOC (Standard of care)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The following medications listed are allowed to be administered during the course of the clinical study.~1. biologic disease-modifying antirheumatic drug (bDMARD)~2. conventional synthetic disease-modifying antirheumatic drug (csDMARD)
Trial: NCT06306339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo for Burfiralimab (hzVSF-v13)
Trial: NCT05619328
Drug: Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, with some liquid with or after a meal
Trial: NCT06087770
Drug: SM3321
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion, once a week, 28 days for a dosing cycle
Trial: NCT06383819
Drug: Longidaza®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose 3000 IU intramuscularly once every 5 days, 15 injections
Trial: NCT05620589
Drug: Amoxicillin + Tetracycline + Bismuth + Esomeprazole
RxNorm normalized name: bismuth biskalcitrate / metronidazole / tetracycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Esomeprazole 40mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 40mg bid
Trial: NCT06383819
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intramuscularly once every 5 days, 15 injections
Trial: NCT05620589
Drug: Amoxicillin + Tetracycline + Bismuth + Vonoprazan
RxNorm normalized name: bismuth biskalcitrate / metronidazole / tetracycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth +Vonoprazan 20mg bid or Amoxicillin1000mg bid+ Tetracycline 500mg tid+ Bismuth + Vonoprazan 20mg bid
Trial: NCT05620589
Drug: Amoxicillin + Tetracycline + Bismuth + Tegoprazan
RxNorm normalized name: bismuth biskalcitrate / metronidazole / tetracycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Tegopraza 50mg bid
Trial: NCT04590118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of 1 ml/kg placebo
Trial: NCT03567824
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will have the same appearance, taste, odor and mode of administration as MLD10.
Trial: NCT06402019
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group went under multiple sessions of normal saline injection.
Trial: NCT04849351
Drug: HMPL-689
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients are to receive monotherapy of HMPL-689 30 mg QD continuously in 28-day treatment cycles.
Trial: NCT04530474
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive medication as a one time dose
Trial: NCT05977036
Drug: CDK4/6 + Endocrine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDA-approved endocrine therapy plus CDK4/6 inhibitor. Ribociclib is the preferred CDK4/6 inhibitor. In the event this drug cannot be obtained due to insurance authorization or if there are specific side effect profile concerns from the treating physician, an alternative CDK4/6 inhibitor is allowed.
Trial: NCT01028313
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg PO three times weekly
Trial: NCT04958876
Drug: SP-104
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule once daily
Trial: NCT05130047
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldafermin placebo solution
Trial: NCT04852367
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin infusion
Trial: NCT04852367
Drug: ThermoDox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ThermoDox infusion
Trial: NCT00561366
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo t.i.d.
Trial: NCT06000137
Drug: Sufentanil injection
RxNorm normalized name: sufentanil Injection
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sufentanil for patient-controlled analgesia
Trial: NCT06000137
Drug: Flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen for patient-controlled analgesia
Trial: NCT02354612
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: companion therapy selection depends on companion therapy used in the parent study
Trial: NCT05446233
Drug: [14C] Antaitavir Hasophate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg suspension containing 200µCi of \[14C\] Antaitavir Hasophate
Trial: NCT04026880
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered by intramuscular injection weekly for 12 weeks
Trial: NCT05189873
Drug: Long GnRH agonist + HRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group:(Long GnRH agonist + HRT) From day 18-21 of the previous cycle, 0.5 cc of Superfect is injected daily and vaginal ultrasound is performed 10-14 days later If the endometrial thickness is less than 5 mm and there are no ovarian cysts, estradiol is started like HRT treatment and the agonist dose of GnRH starts with estradiol. It is halved (0.25 cc superfect) and superfect is prescribed until progesterone is started. At the time of progesterone administration, the administration of superfect is discontinued. Injections of estradiol and progesterone is the same as for the HRT group
Trial: NCT05486416
Drug: HSK3486
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK3486 for induction of general anesthesia
Trial: NCT03866499
Drug: Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg gefitinib placebo tablet, QD
Trial: NCT03866499
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg BPI-7711 placebo capsule, QD
Trial: NCT05416073
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PCIA formula：100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline.~30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min. After that, the intravenous analgesia pump was started. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h.~The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.
Trial: NCT04452565
Drug: Drug: NA-831
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NA-831 is a neuroprotective drug, available at 30 mg capsule
Trial: NCT05216497
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-2 capsules for 7 days on top of standard therapy
Trial: NCT06349486
Drug: rabeprazole, amoxicillin, clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: proton pump inhibitor-based standard triple therapy
Trial: NCT05303220
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified Dose on specified days
Trial: NCT05303701
Drug: GV1001 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline
Trial: NCT05303701
Drug: GV1001 1.12mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized peptide from hTERT
Trial: NCT05852769
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05852769
Drug: Flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05852769
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06196632
Drug: Peginterferon-α; Nucleoside analogs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with chronic hepatitis B were treated with the combination of peginterferon-α and nucleoside analogs
Trial: NCT04825561
Drug: AD-208
RxNorm normalized name: testosterone 0.208 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 24weeks
Trial: NCT04825561
Drug: placebo of AD-208
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 24weeks
Trial: NCT04825561
Drug: placebo of AD-2081
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 24weeks
Trial: NCT04702360
Drug: ELX/TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablet for oral administration.
Trial: NCT05571345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match PF614 capsules will be provided by the sponsor.
Trial: NCT05553405
Drug: Intralipid Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid 20% (a 20% IV fat emulsion) is a sterile, non-pyrogenic fat emulsion prepared for IV administration as a source of calories and essential fatty acids. It is made up of 20% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin and water for injection. In addition, sodium hydroxide has been added to adjust the pH so that the final product pH is 8.
Trial: NCT06606483
Drug: MDR-001
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of small molecule MDR-001 tablets
Trial: NCT06606483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally placebo
Trial: NCT04531865
Drug: Placebo tablets matching Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Addition of Maintenance Placebo tablets matching Mycophenolate Mofetil from 4 Month onwards. Dose: 20\~30mg/kg/day，BID. Total duration : 8 months.
Trial: NCT04830735
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05559008
Drug: SHR2554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes
Trial: NCT04789304
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06388772
Drug: QHRD106 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250IU\~8400IU,pegylated(PEG)-tissue kallikrein-1
Trial: NCT06388772
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT05079451
Drug: 3BNC117-LS
RxNorm normalized name: Emcor LS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3BNC117-LS will be administered by intravenous infusion (directly into the participants vein) over a period of 30 to 60 minutes. The total time needed to administer the study drug may be longer, based on factors such as participant tolerance. The participant's dose will be calculated using their most current weight on record.
Trial: NCT05182944
Drug: A：non-pCR patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（2-4 cycles Camrelizumab+Albumin Paclitaxel+Cisplatin and Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication
Trial: NCT05182944
Drug: B：non-pCR patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication
Trial: NCT05182944
Drug: A：pCR patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication
Trial: NCT05182944
Drug: B：pCR patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Best Supportive Care）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication
Trial: NCT04821687
Drug: Madopar Tab. 125 or Perkin Tab. 25-100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Madopar Tab. 125 or Perkin Tab. 25-100mg will be added to current and stable therapy of L-DOPA/DDCI
Trial: NCT00215917
Drug: D-serine 2100 mg daily
RxNorm normalized name: D-Serine
DrugBank: D-Serine (DB03929)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05573230
Drug: LY3502970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05232552
Drug: induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: docetaxel 75mg/m2 d1 plus DDP 75mg/m2 d1 for 3 cycles every 21days
Trial: NCT03787082
Drug: Placebo Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile water (15mL) mouth rinse for 1 minute
Trial: NCT04940026
Drug: [14C]-SAR439859 microtracer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion Intravenous
Trial: NCT04940026
Drug: [14C]-SAR439859
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder for oral solution Oral
Trial: NCT05663892
Drug: Biktarvy 50/200/25 Tab
RxNorm normalized name: BIKTARVY 50/200/25 TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As the HIV ART, the combination of B/F/TAF, known as Biktarvy®, which is a widely available Single Tablet Regimen (STR) approved by Health Canada is the drug under investigation. Participants in groups 1 and 2 will either have to already be taking B/F/TAF or will be required to switch to it at baseline and they will self-administer B/F/TAF once daily in the morning, with or without food. Participants taking their dosage at night will be required to switch to a morning dose at the screening visit.
Trial: NCT05663892
Drug: Estradiol Tablets
RxNorm normalized name: Estradiol Tablets
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 17(beta)-estradiol as the estrogen and an anti-androgen (pharmaceutical \[e.g., spironolactone, cyproterone, finasteride, leuprolide, bicalutamide, dutasteride\] and/or surgical \[orchiectomy\] and/or medical \[hypogonadism\]).Doses of estradiol range from 1 mg to a maximum of 6 mg per day.~Participants must take 2 mg until the Month 2 Visit. Trans women participants in both groups 1 and 3 must divide their dose to twice a day (BID) if they are taking \> 2 mg per day and take 2 mg in the morning and the rest of the dosing in the evening. Participants who are only taking 2mg of estradiol once daily at night must switch their dosing to the morning. Participants who either crush or take the oral estradiol sublingually must switch to swallowing the tablet orally from the day after the screening visit until the Month 2 visit, otherwise the estradiol concentrations will be markedly higher.
Trial: NCT05697952
Drug: E1K 1,200 ㎍/joint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of E1K 1,200 ㎍/joint/ml on target lesion
Trial: NCT05697952
Drug: E1K 2,400 ㎍/joint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of E1K 2,400 ㎍/joint/ml on target lesion
Trial: NCT05697952
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 3ml saline on target lesion
Trial: NCT05449899
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3,-2.
Trial: NCT06297512
Drug: Radiotherapy, Temozolomide, Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation treatment Concomitant TMZ: 75mg/m2/day per OS for 7 days per week, from the first day of radiotherapy to the last (maximum cumulative dose 3150mg/m2), with possibility of earlier initiation on clinician's judgment.~After 1 month (4-5 weeks ± 7 days) from the end of RT/TMZ treatment they will receive:~Adjuvant TMZ: 2 cycles at increasing doses (150-180 mg/m2) per OS for 5 consecutive days 28 days apart~After 3 months (12 weeks ± 7 days) from the end of RT/TMZ treatment they will receive:~Dox 4 cycles with 37.5mg/m2/day by continuous infusion over 48 hours (2 days) every 28 days (maximum cumulative dose 300mg/m2)~And after 4 weeks ± 7 days from the end of Dox treatment they will receive:~TMZ adjuvant 12 cycles at increasing doses (150-180 mg/m2) by OS for 5 consecutive days 28 days apart (maximum cumulative dose 16200 mg/m2);
Trial: NCT04677179
Drug: LY3471851
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered SC
Trial: NCT04677179
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered SC
Trial: NCT05090280
Drug: PF614 solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF614 solution is an oxycodone prodrug
Trial: NCT05004571
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT03149211
Drug: current standard HAART treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive current standard HAART treatment as the active control group.
Trial: NCT05188339
Drug: 4% sodium citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of 4% sodium citrate is also according to catheter lumen (LVR) instilled into each lumen of catheter after HD session, eg. 1.6 cc/lumen for LV R 1.6, 1.8 cc/lumen for LVR 1.8.~A prospective, open label, control study. The content of study protocol will be posted in the HD room in the Kaohsiung Chang Gung memorial Hospital, Taiwan. After inform consent obtained, we will categorize enrolled participants randomly into two groups, 4% sodium citrate group(experimental group), heparin group(control group), respectively. The study duration is three months.
Trial: NCT05188339
Drug: heparin group
RxNorm normalized name: Heparin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin dosage is based on volume ratio in catheter lumen (LVR) after each HD session, eg. 8000u/lumen in 1.6 LVR, 9000u/lumen in LVR 1.8.
Trial: NCT04880109
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of placebo capsule once daily for 14 days
Trial: NCT06610305
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1 mg/day delivered via weekly patch
Trial: NCT06609941
Drug: Pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this group will only be provided with standard pharmacological management for 4 weeks as prescribed by a pulmonologist. For example:~Salbutamol inhaler (Short acting bronchodilator) Saltra inhaler (Selective long acting β2 adrenoceptor agonist) Tiotropium (Anticholinergic) Combivir (Nucleoside analogue - reverse transcriptase inhibitor) etc.~Week 01 and week 02:~Patients will receive medication prescribed by pulmonologist.~Week 03 and week 04:~Patients will receive medication prescribed by pulmonologist.
Trial: NCT06609759
Drug: Standard chemotherapy regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In terms of postoperative adjuvant treatment, treatment is based on the guideline standard treatment plan, which can be adjusted according to the doctor's experience.